Bilirubin

metabolite

Bilirubin exerts antioxidant and antithrombotic effects, with low levels predicting thrombus burden and adverse outcomes in Type 1 MI.

Pathway placement

Cascade stepPlaque inflammation

Confidencemedium

RationaleAntioxidant reducing thrombosis; predicts adverse events and thrombus burden in atherosclerotic CAD/STEMI.

Also acts inPlatelet activation

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresType-II-associated

R — rupture / Type-I

—

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-51.7

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationmag 2

2anemia / acute blood lossmag 2

3hypovolemia / dehydrationmag 2

4tachyarrhythmian/a

5hypoxemia / respiratory failuremag 2

6hypertensive emergencymag 2

7high-demand / peri-operative stressn/a

Coverage: 5/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 15 supporting references. See the discrimination table for all markers.

Validated clinical assay

Specimen

Serum or plasma (protect from light)

Collection tube

Serum separator (gold/red-top, SST) · Lithium heparin (green-top)

Method / principle

Diazo (Jendrassik-Grof) or vanadate oxidation

Reagent / substrate

Diazotized sulfanilic acid → azobilirubin, read 540 nm

Platform

Automated analyzer

Turnaround · availability

Routine · Universal